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Objectives: The purpose of this meta-analysis was to examine the effectiveness of silver-impregnated
central venous catheters (CVCs) in preventing catheter bacterial colonization and catheter-related blood
stream infections (CRBSIs).
Methods: PubMed, Cochrane, and Embase databases were searched up to April 30, 2014. Studies in
which other antiseptic reagents were used (e.g., chlorhexidine, octenidine dihydrochloride, urokinase
rinses, benzalkonium chloride, rifampin–minocycline) were excluded. Pooled odds ratios (ORs) and 95%
conﬁdence intervals (CIs) were calculated. Tests of heterogeneity and publication bias were performed.
Results: Twelve studies were included in the meta-analysis. The studies enrolled a total of 2854 patients;
1440 received a standard CVC and 1414 received a silver-impregnated CVC. No signiﬁcant difference in
catheter bacterial colonization rates was found between silver-impregnated and standard CVCs (OR
0.907, 95% CI 0.758–1.087, p = 0.290). No signiﬁcant difference in CRBSI rates was found between silver-
impregnated and standard CVCs (pooled OR 0.721, 95% CI 0.476–1.094, p = 0.124). No signiﬁcant
heterogeneity or publication bias was noted.
Conclusions: Silver-impregnated CVCs are not associated with reduced rates of bacterial colonization or
CRBSI.
 2014 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Central venous catheters (CVCs) are used for the administration
of medications, intravenous ﬂuids, and blood products, nutritional
support, and for monitoring hemodynamics in critically ill
patients. However, their use is associated with bacterial coloniza-
tion of the catheter and an increased incidence of blood stream
infections (catheter-related blood stream infections; CRBSIs).1–5
Risk factors for CRBSIs are numerous and include the disease and
condition of the patient, material the catheter is made of, and
length of time the catheter is in place.6–10 It is estimated that in the
USA there are approximately 250 000 cases of CRBSI yearly.4
CRBSIs are a signiﬁcant problem in developing countries. The
International Nosocomial Infection Control Consortium (INICC)
report, data summary of 43 countries for 2007–2012, which
included 503 intensive care units in Latin America, Asia, Africa, and* Corresponding authors. Tel.: +86 021 66307542; fax: +86 021 66303012.
E-mail addresses: shlzk2002@163.com (Y. Shi), liuzhanju88@126.com (Z.-J. Liu).
1 Both these authors are co-ﬁrst author.
http://dx.doi.org/10.1016/j.ijid.2014.09.018
1201-9712/ 2014 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/3.0/).Europe, found that the pooled rate of CRBSI in the INICC intensive
care units (ICUs) of 4.9 per 1000 central line-days was almost 5-
fold higher than the rate in comparable hospitals in the USA
(0.9 per 1000 central line-days).11 Furthermore, CRBSIs place a
substantial economic burden on developing countries, where extra
costs associated with a CRBSI have been estimated to range from
$4888 to $11 591,12,13 as well as placing an additional economic
burden on developed countries.14
One of the methods examined to reduce the incidence of CRBSIs
is impregnating or coating catheters with anti-infective agents
including antiseptics, antibiotics, and antimetabolites.5,15,16 Al-
though results of individual studies have been conﬂicting, data have
indicated that minocycline and rifampin-impregnated catheters are
associated with lower rates of colonization and infection,17–19 and a
recent Cochrane systematic review concluded that while impreg-
nated catheters in general reduce catheter colonization and CRBSIs,
they may not be effective in all patient populations.3
Silver is non-toxic and has broad-spectrum antimicrobial
activity,20 and as such the use of silver in CVCs in an attempt to
reduce catheter colonization and CRBSIs has been examined.
Catheters can be coated internally and/or externally withious Diseases. This is an open access article under the CC BY-NC-ND license (http://
Figure 1. Flow diagram of study selection.
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on the effectiveness of silver to reduce catheter bacterial
colonization and CRBSI are not consistent.22–24
The purpose of this systematic review of the literature and
meta-analysis was to compare the effectiveness of silver-impreg-
nated catheters with that of standard catheters for the prevention
of CRBSI.
2. Materials and methods
2.1. Search strategy and selection criteria
PubMed, Cochrane, and Embase databases were searched on
April 30, 2014 using combinations of the following search terms:
central venous catheter, bloodstream infection, infection, silver-
impregnated, silver-coated, antiseptic, bacterial colonization.
Reference lists of relevant studies were hand-searched. Inclusion
criteria were: (1) randomized controlled trial (RCT) or comparative
prospective study; (2) patients had received a silver-impregnated
CVC or standard non-impregnated polyurethane CVC; (3) rates of
bacterial colonization (catheter tip colonization) and/or rates of
CVC-associated bloodstream infection had been evaluated. Studies
in which other antiseptic reagents were used (e.g., chlorhexidine,
octenidine dihydrochloride, urokinase rinses, benzalkonium chlo-
ride, rifampin–minocycline), those that did not report a quantita-
tive outcome, and those that did not have an RCT or comparative
prospective design were excluded.
2.2. Study selection and data extraction
Studies were identiﬁed using the search strategy by two
independent reviewers. Where there was uncertainty regarding
eligibility, a third reviewer was consulted. The following informa-
tion/data were extracted from studies that met the inclusion
criteria: name of the ﬁrst author, year of publication, study design,
number of participants in each group, age of participants, gender,
type of catheter, duration of catheter placement, rates of catheter
bacterial colonization, CRBSI, and catheter-related infection (CRI),
ICU stay, and ICU mortality rates.
2.3. Quantitative data synthesis and outcome measures
The outcome measures were catheter bacterial colonization
and CRBSI rates. The odds ratios (ORs) and 95% conﬁdence intervals
(CIs) of bacterial colonization and CRBSI in the patients with silver-
impregnated CVCs compared to standard CVCs were calculated to
evaluate the efﬁcacy of silver-impregnated CVCs compared to
standard CVCs. Heterogeneity among the studies was assessed by
Cochran Q and I2 statistic. For the Q statistic, statistically signiﬁcant
heterogeneity is indicated when p < 0.10. The percentage of the
observed between-study variability caused by heterogeneity is
indicated by the I2 statistic, and heterogeneity was deﬁned as
follows: 0–24% = no heterogeneity; 25–49% = moderate heteroge-
neity; 50–74% = large heterogeneity; and 75–100% = extreme
heterogeneity. If heterogeneity existed between studies (a Q
statistic with p < 0.1 or an I2 statistic >50%),25,26 a random-effects
model (DerSimonian–Laird method) was performed.27 Otherwise,
a ﬁxed-effect model was used (Mantel–Haenszel method). A
sensitivity analysis was performed based on the leave-one-out
approach. Funnel plots with one-sided Egger’s tests were
performed to evaluate publication bias for the meta-analyses.
The homogeneity test, pooled estimates for the ORs of bacterial
colonization and CRBSI, and corresponding sensitivity analysis
were performed using Comprehensive Meta-Analysis software,
version 2.0 (Biostat, Englewood, NJ, USA). Values of p < 0.05 were
considered to indicate statistical signiﬁcance.3. Results
3.1. Literature search
A summary of the literature search results and study selection is
shown in Figure 1. After initially identifying 227 articles, 175 were
excluded and 42 were included in the full text review. Of these
42 articles, 30 were excluded (one was a duplicate, seven provided
no outcome of interest, and in 22 another antiseptic agent was
used). Thus, 12 studies were included in the meta-analysis.9,28–38
3.2. Study characteristics
Of the 12 studies included in the meta-analysis, all were RCTs
except for that of Khare et al. (2007),31 which was a prospective
cohort study. The studies enrolled a total of 2854 patients who
required CVCs; 1440 patients received a standard CVC and
1414 received a silver-impregnated CVC. The characteristics of
the patients included in the studies, including the number of
patients, age, sex, and catheter duration, are summarized in
Table 1. Outcomes, including bacterial colonization rates, CRBSI,
CRI, intensive care unit (ICU) stay, and ICU mortality are
summarized in Table 2. Characteristics of the catheters are shown
in Table 3.
3.3. Outcomes
3.3.1. Catheter colonization
Eleven of the studies reported catheter colonization out-
comes.9,28,35,37,38 Ten9,28–30,32–35,37,38 of the 11 studies showed
no signiﬁcant difference in bacterial colonization between silver-
impregnated and standard CVCs. Meta-analysis including the
11 studies revealed no signiﬁcant difference in bacterial coloniza-
tion between silver-impregnated and standard CVCs (pooled OR
0.907, 95% CI 0.758–1.087, p = 0.290; Figure 2). A ﬁxed model of
analysis was used as no obvious heterogeneity was noted among
the studies (Cochran Q = 15.14, p = 0.127, I2 = 33.94). Egger’s test
for the intercept in the funnel plot showed no signiﬁcant
publication bias among the studies (intercept = 1.36, one-tailed
p = 0.216; Figure 3). The sensitivity analysis showed that the
pooled OR of catheter colonization with each of the studies
removed in-turn remained < 1.0 and not statistically signiﬁcant;
this indicated no obvious inﬂuence of any individual study on the
pooled OR of all included studies (Table 4).
3.3.2. CRBSI
Nine studies28–32,34–37 reported CRBSI outcomes, and all
indicated there was no signiﬁcant difference in the risk of CRBSI
Table 2
Study outcomes
First author
(year of publication)
Catheter colonization, n/
total
CRBSI, n/total CRI, n/total ICU stay, days ICU mortality, count/
total
Standard
CVC
Silver-
impregnated
CVC
Standard
CVC
Silver-
impregnated
CVC
Standard
CVC
Silver-
impregnated
CVC
Standard
CVC
Silver-
impregnated
CVC
Standard
CVC
Silver-
impregnated
CVC
Antonelli (2012)28 41/137 44/135 7/137 6/135 NR NR NR NR 59/137 62/135
Arvaniti (2012)29 24/156 25/159 2/156 2/159 NR NR NR NR 45/156 39 /159
Hagau (2009)30 38/141 30/131 8/141 4/131 NR NR 12.13 (9.51) 16.66 (14.35) NR NR
Khare (2007)31 91/124 71/122 4/124 4/122 NR NR NR NR NR NR
Kalfon (2007)32 36/297 47/320 8/297 8/320 NR NR NR NR NR NR
Du¨nser (2005)33 19/160 27/160 NR NR NR NR 26 (16) 25 (16) 23/120 12/85
Corral (2003)34 41/103 29/103 4/103 1/103 NR NR NR NR NR NR
Bong (2003)35 48/142 47/128 11/142 7/128 NR NR NR NR NR NR
Harter (2002)36 NR NR 10 /113 6/120 24/113 12/120 NR NR 0 0
Stoiser (2002)37 14/47 10/50 3/47 3/50 NR NR NR NR NR NR
Bo¨swald (1999)9 18/79 12/86 NR NR 13/79 4/86 NR NR NR NR
Trerotola (1998)38 7/44 8/47 NR NR 6/44 5/77 NR NR NR NR
NR, not reported; CRBSI, catheter-related blood stream infection; CRI, catheter-related infection; CVC, central venous catheter; ICU, intensive care unit.
ICU stay is reported as the mean (standard deviation).
Table 1
Basic characteristics of the studies includeda
First author
(year of publication)
Number of patients Age, years Gender, F/M Catheter duration, days
Standard
CVC
Silver-
impregnated
CVC
Standard
CVC
Silver-
impregnated
CVC
Standard
CVC
Silver-
impregnated
CVC
Standard
CVC
Silver-
impregnated
CVC
Antonelli (2012)28 137 135 62.9 (17.3) 64.8 (16.6) 59/78 48/87 15 (37) 13 (24)
Arvaniti (2012)29 156 159 59 (40, 72)* 63 (46, 73)* 44/112 56/103 7 (5, 9)* 7 (5, 9)*
Hagau (2009)30 121 109 56 (20) 55 (17) 121/69 109/65 8.2 (4.1) 9.7 (4.3)
Khare (2007)31 112 102 68* 65* 50/62 39/63 7 (2, 18)y 7 (3, 21)y
Kalfon (2007)32 297 320 61 (17) 61 (15) 102/195 113/207 10 (9, 11)z 10 (9, 11)z
Du¨nser (2005)33 120 85 60 (16) 63 (16) 32/88 28/57 10.7 (4.2) 9.3 (4)
Corral (2003)34 65 80 58 (18) 56 (18) 26/39 25/55 13.6 12.2
Bong (2003)35 142 128 59* 55* NR NR 14 10.5
Harter (2002)36 113 120 45 (18, 71)y 43 (19, 74)y 59/54 76/44 13.3 (9.0) 12.8 (8.3)
Stoiser (2002)37 47 50 52 (24, 81)y 51 (20, 84)y 21/26 27/23 11 (4, 46)y 10.5 (3, 39)y
Bo¨swald (1999)9 86 79 53* 55* 23/56 38/48 8 (5, 51)y 9 (5, 27)y
Trerotola (1998)38 44 47 50 53 17/27 22/25 125 61
F, female; M, male; NR, not reported; CVC, central venous catheter.
a All of the studies included were randomized control trials (RCT), except for Khare (2007), which was a prospective cohort study. Age and catheter duration presented as
the mean (standard deviation), *median (interquartile range), ymedian (range), or zmedian (95% conﬁdence interval).
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including the nine studies revealed no signiﬁcant difference in
CRBSI between silver-impregnated and standard CVCs (pooled OR
0.721, 95% CI 0.476–1.094, p = 0.124; Figure 4). A ﬁxed model of
analysis was used as no obvious heterogeneity was noted among
the studies (Cochran Q = 2.25, p = 0.972, I2 = 0). Egger’s test for the
intercept in the funnel plot showed no signiﬁcant publication bias
among the studies (intercept = 0.35, one-tailed p = 0.323;
Figure 5). The sensitivity analysis showed that the pooled OR of
CRBSI with each of the studies removed in-turn remained <1.0 and
not statistically signiﬁcant; this indicated no obvious inﬂuence of
any individual study on the pooled OR of all included studies
(Table 4).
4. Discussion
The results of this meta-analysis including 11 RCTs and one
prospective cohort study indicate that silver-impregnated CVCs
are not associated with lower rates of catheter bacterial coloniza-
tion and do not reduce the incidence of CRBSI as compared to
standard CVCs. To reduce bias as a result of heterogeneity of
materials, we excluded studies of silver-coated catheters and those
that used antiseptic agents such as chlorhexidine, octenidinedihydrochloride, urokinase rinses, benzalkonium chloride, and
rifampin–minocycline, so that this study focused only on silver-
impregnated catheters.
The use of a CVC is necessary for the care of most critically ill
patients, the administration of chemotherapeutic agents, and for
patients who require long-term care and interventions such as
parenteral nutrition. However, CVCs are associated with blood
stream infections, which in many cases are life-threatening and are
associated with markedly increased health care costs.4,16 CRBSIs
are thought to be due to colonization of the intravascular portion of
the catheter that occurs during insertion, or the migration of
bacteria from the skin or catheter port.5,15,39 Guidelines estab-
lished for the placement and care of CVCs, including hand hygiene,
maximal barrier precautions during insertion, chlorhexidine skin
antisepsis, proper catheter site selection with the subclavian vein
as the preferred site for non-tunneled catheters, and daily
examination of catheter necessity with removal of non-necessary
catheters, has reduced the incidence of CRBSI.4,6
Changes in the design and materials of catheters have also been
examined in attempts to reduce the incidence of CRBSI. For
example, polytetraﬂuoroethylene and polyurethane catheters are
associated with lower rates of infection than those made of
polyvinyl chloride or polyethylene.40 Analysis of the bonding or
Table 3
Catheter characteristics
First author
(year of publication)
Number of
lumens
Catheter type Catheter sites
Standard CVC Silver-impregnated CVC Standard CVC Silver-impregnated CVC
Antonelli (2012)28 3 Standard triple-lumen,
non-impregnated
AgTive triple-lumen, silver-
nanoparticle-impregnated
Subclavian or jugular
Arvaniti (2012)29 3 Polyurethane, non-impregnated,
non-heparin-bonded
Oligon Vantex silver–platinum–carbon Internal jugular (19.2%), subclavian
(34%), femoral (47%)
Internal jugular (21%), subclavian
(34%), femoral (45%)
Hagau (2009)30 2 or 3 Standard polyurethane central venous
Vygon
Silver-integrated Multicath Expert
Vygon
Jugularis internal vein (64%),
subclavian (34%)
Jugularis internal vein (59%),
subclavian (41%)
Khare (2007)31 4 Non-impregnated polyurethane Silver zeolite-impregnated
polyurethane
NR NR
Kalfon (2007)32 2 or 3 Standard polyurethane central venous
Vygon
Silver-integrated Multicath Expert
Vygon
Internal jugular (46%), subclavian
(45%), femoral (8%)
Internal jugular (43%), subclavian
(50%), femoral (7%)
Du¨nser (2005)33 3 or 4 Non-impregnated polyurethane Polyurethane externally impregnated
with silver
It was aimed to place CVCs via the
subclavian route. The internal jugular
and femoral sites were considered
alternative approaches in patients with
existing bilateral subclavian catheters
in place, permanent transvenous
pacemakers, or an anatomical situation
making central venous cannulation via
the subclavian route impossible
Corral (2003)34 3 Non-impregnated polyurethane Oligon Vantex silver–platinum–carbon Subclavian (38%), internal jugular
(29%), femoral (33%)
Subclavian (45%), internal jugular
(15%), femoral (42%)
Bong (2003)35 1 Non-impregnated polyurethane Oligon Vantex silver–platinum–carbon Subclavian (100%) Subclavian (100%)
Harter (2002)36 1 Non-impregnated polyurethane Polyurethane externally impregnated
with silver
Jugular (100%) Jugular (100%)
Stoiser (2002)37 3 Non-impregnated polyurethane Silver-impregnated Subclavian (32%), jugular (68%) Subclavian (74%), jugular (26%)
Bo¨swald (1999)9 1, 2, 3, or 4 Non-impregnated polyurethane Silver-impregnated polyurethane
containing 0.3–0.6 weight/volume % of
silver of highest purity (99.999%)
Jugular (90%), subclavian (10%) Jugular (94%), subclavian (6%)
Trerotola (1998)38 2 Non-impregnated polyurethane Silver-impregnated Right internal jugular (100%) Right internal jugular (100%)
CVC, central venous catheter; NR, not reported.
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Figure 3. Funnel plot for catheter colonization.
Figure 2. Meta-analysis of catheter colonization.
Table 4
Sensitivity analysis for catheter colonization and CRBSI meta-analyses
Outcome Study Results with study removed
Point Lower limit Upper limit Z-value p-Value
Bacterial colonization Antonelli (2012)28 0.880 0.726 1.066 1.307 0.191
Arvaniti (2012)29 0.897 0.743 1.083 1.132 0.258
Hagau (2009)30 0.920 0.761 1.114 0.852 0.394
Khare (2007)31 0.978 0.807 1.184 0.233 0.816
Kalfon (2007)32 0.858 0.706 1.043 1.537 0.124
Du¨nser (2005)33 0.868 0.719 1.047 1.480 0.139
Corral (2003)34 0.949 0.785 1.147 0.540 0.589
Bong (2003)35 0.877 0.723 1.064 1.327 0.185
Stoiser (2002)37 0.923 0.768 1.109 0.859 0.390
Bo¨swald (1999)9 0.932 0.774 1.121 0.750 0.453
Trerotola (1998)38 0.903 0.752 1.084 1.095 0.274
Pooled estimate for all studies (ﬁxed) 0.907 0.758 1.087 1.057 0.290
CRBSI Antonelli (2012)28 0.701 0.447 1.097 1.554 0.120
Arvaniti (2012)29 0.711 0.464 1.089 1.569 0.117
Hagau (2009)30 0.752 0.483 1.171 1.261 0.207
Khare (2007)31 0.698 0.451 1.079 1.617 0.106
Kalfon (2007)32 0.684 0.432 1.082 1.624 0.104
Corral (2003)34 0.751 0.491 1.147 1.325 0.185
Bong (2003)35 0.729 0.460 1.154 1.349 0.177
Harter (2002)36 0.761 0.483 1.198 1.179 0.238
Stoiser (2002)37 0.709 0.461 1.090 1.569 0.117
Pooled estimate for all studies (ﬁxed) 0.721 0.476 1.094 1.538 0.124
CRBSI, catheter-related blood stream infection.
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Figure 5. Funnel plot for catheter-related blood stream infection (CRBSI).
Figure 4. Meta-analysis of catheter-related blood stream infection (CRBSI).
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the fact that materials can be bonded to the inner and/or exterior
surface of the catheter or impregnated within the catheter material
itself.3 In addition, the results can vary with respect to the length of
time in situ of the indwelling catheter,3,24,40 and rates of CRBSI can
be inﬂuenced by the baseline rate of catheter tip colonization.28 In
general, heparin bonding to the catheter material and impregna-
tion with rifampin–minocycline has been shown to reduce the
incidence of CRBSI.21,39 Catheters coated with chlorhexidine and
sulfadiazine are associated with a decreased incidence of catheter
colonization (OR 0.44) and CRBSI (OR 0.56) as compared to
uncoated catheters.22,41 On the other hand, simple silver-
impregnation into the catheter material does not appear to reduce
the rates of colonization or CRBSI.
A systematic review by Gilbert and Harden21 in 2008 reported
no difference in colonization rates or CRBSI between silver-
impregnated catheters and standard catheters. In a 2010 meta-
analysis, Wang et al.24 classiﬁed silver-containing catheters into
three categories: silver alloy-coated, silver-impregnated, and silver
iontophoretic. They found that all three were associated with
lower rates of catheter colonization than standard catheters, but
none provide a reduced rate of CRBSI as compared to standard
catheters. The results did show that minocycline–rifampin
catheters were associated with a signiﬁcantly lower rate of CRBSIthan standard catheters (OR 0.18). A 2013 Cochrane database
systematic review by Lai et al.3 classiﬁed the silver catheters into
three categories: silver platinum–carbon impregnation, silver-
impregnated cuff, and silver impregnation. It was found that none
of the three groups of catheters showed any beneﬁt with respect to
reducing catheter colonization and that only the silver impregna-
tion group was associated with a lower rate of CRBSI. The review
included 56 studies with over 16 000 catheters, and 11 types of
antimicrobial impregnations, and overall the results indicated that
impregnation (with any material, e.g., antibiotics, antiseptics)
signiﬁcantly reduced CRBSI with an absolute risk reduction (ARR)
of 2%, and catheter bacterial colonization with an ARR of 10%.
Interestingly, catheter impregnation did not reduce the rate of
clinically diagnosed sepsis or all-cause mortality.
It is possible that silver-impregnation may have a small impact
on colonization and CRBSI rates; however with the reduction of
infections seen with the optimal care and placement of CVCs, the
impact of silver-impregnated catheters on catheter colonization
rates and CRBSI may have been reduced such that it is not observed
in current studies.10,42
It should be noted that in developing countries and limited-
resource hospital settings, the rate of CRBSI has been reduced
successfully without the use of silver-impregnated CVCs. Numer-
ous studies have shown that the implementation of bundles and
Y.-M. Chen et al. / International Journal of Infectious Diseases 29 (2014) 279–286 285other interventions, such as described for the INICC multidimen-
sional infection control approach, have reduced CRBSIs by up to
50% or more,43–49 and CRBSI-associated deaths by 58%.43 Elements
of the multidimensional infection control approach include: (1)
central line care bundle, (2) education, (3) outcome surveillance,
(4) process surveillance, (5) feedback on CRBSI rates and their
consequences, and (6) performance feedback of infection control
practices.45
There are limitations of this study that should be considered.
First is the lack of blinding of participants and clinicians. Only
Arvaniti et al.29 reported the blinding of outcome assessments. It
should be noted, however, that blinding of different catheter types
is difﬁcult. There was heterogeneity in the types of patients
included in the studies; most studies examined ICU patients, while
Harter et al.36 studied hematology/oncology patients, Trerotola
et al.38 hemodialysis patients, and Stoiser et al.37 immunocom-
promised patients. There was also marked heterogeneity in the
types of silver-impregnated catheter used, and the methods of
analysis and deﬁnitions of catheter colonization varied among the
studies included. Lastly, ICU stay and mortality could not be
assessed because the majority of the studies did not report these
data.
In conclusion, silver-impregnated CVCs are not associated with
lower rates of catheter bacterial colonization and do not reduce the
incidence of CRBSI as compared to standard CVCs. Other options,
such as rifampin–minocycline or chlorhexidine–silver sulfadiazine
impregnated/coated catheters may be considered to reduce the
rate of CRBSI.
Conﬂict of interest: No conﬂict of interest to declare.
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